Difference between revisions of "SMARCB1"

From Libre Pathology
Jump to navigation Jump to search
(wrong link removed again (it is for EMA not for INI1))
Line 30: Line 30:
{{Reflist|1}}
{{Reflist|1}}


==External links==
*[http://www.nordiqc.org/Epitopes/EMA/EMA.htm EMA (nordiqc.org)].


[[Category:Immunohistochemistry]]
[[Category:Immunohistochemistry]]

Revision as of 07:49, 23 September 2015

SMARCB1
Immunostain in short

INI1-ve in AT/RT.
Abbreviation SMARCB1, BAF47
Normal staining pattern nuclear staining
Positive any healthy tissue
Negative AT/RT, renal rhabdoid tumour, extrarenal malignant rhabdoid tumour, atypical teratoid/rhabdoid tumour, epithelioid sarcoma

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1, commonly abbreviated SMARCB1 (or INI1 or BAF47), is a diagnostic immunostain, because nuclear staining is lost in some specific types of cancer shown below.

Negative

See also

References

  1. Hornick, Jason (2009). "Loss of INI1 expression is characteristic of both conventional and proximal-type epithelioid sarcoma". American Journal of Surgical Pathology.
  2. Jackson EM, Sievert AJ, Gai X et al. (March 2009). "Genomic analysis using high-density single nucleotide polymorphism-based oligonucleotide arrays and multiplex ligation-dependent probe amplification provides a comprehensive analysis of INI1/SMARCB1 in malignant rhabdoid tumors". Clin. Cancer Res. 15 (6): 1923–30.
  3. Bishop, JA.; Antonescu, CR.; Westra, WH. (Sep 2014). "SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract.". Am J Surg Pathol 38 (9): 1282-9. doi:10.1097/PAS.0000000000000285. PMID 25007146.
  4. Hasselblatt, M.; Isken, S.; Linge, A.; Eikmeier, K.; Jeibmann, A.; Oyen, F.; Nagel, I.; Richter, J. et al. (Feb 2013). "High-resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors.". Genes Chromosomes Cancer 52 (2): 185-90. doi:10.1002/gcc.22018. PMID 23074045.